Novartis Spent $2 Million Lobbying in First Quarter
May 25, 2010
The Associated Press reports that drug developer Novartis spent about $2 million in the first quarter lobbying the U.S. government on prescription drug issues and other legislation, according to a recent disclosure form. The spending marks a 51 percent boost from just over $1.3 million spent in the year-ago period, and is up from the $1.57 million spent in the 2009 fourth quarter. Novartis makes flu vaccines and a range of pharmaceuticals. The Swiss company lobbied on bills focusing on health reform issues, market access issues, drug importation, and biosimilars or copies of biotech-based drugs. The company also lobbied on global trade issues, pandemic flu treatment funding, and Medicare coverage issues, according to the filing with the House clerk''s office on April 20. Aside from Congress, the company also lobbied the Departments of Commerce, Defense, and Health and Human Services during the January to March period.